Alaunos (TCRT) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$3,000.00

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

$3,000.00

Gross margin

100.00%

Net income (trailing twelve months)

−$4.0M

Net income (quarter)

−$952,000.00

Net income growth (year over year)

+9.42%

Net margin

−133666.67%

Return on equity

−190.86%

EPS (trailing twelve months)

−$1.75

Book value per share

$0.26

P/E (trailing twelve months)

—

Price to book

9.29

Debt to assets

56.99%

Payout ratio

—

Dividend yield

—

Company profile

Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.

• Is Alaunos (TCRT) profitable?

  No. Alaunos reported a net loss of $4.0M over the trailing twelve months.

• How much revenue does Alaunos (TCRT) make?

  Alaunos generated $3,000.00 in revenue over the trailing twelve months.

• How do I buy stock in Alaunos (TCRT)?

  TCRT trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.